Welcome to our dedicated page for Chemomab Therapeutics SEC filings (Ticker: CMMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Chemomab Therapeutics Ltd. (CMMB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Chemomab files annual reports on Form 20-F and current reports on Form 6-K, which together offer insight into its clinical-stage biotechnology business focused on nebokitug, a monoclonal antibody targeting CCL24 in fibro-inflammatory diseases such as primary sclerosing cholangitis (PSC).
Through its Form 6-K submissions, Chemomab furnishes press releases, unaudited condensed consolidated financial statements, and management’s discussion and analysis for interim periods. These filings detail research and development spending, general and administrative expenses, cash resources and liquidity outlook, as well as narrative updates on the nebokitug development program, including the Phase 2 SPRING trial in PSC and preparations for a planned Phase 3 registration study. Certain 6-Ks also incorporate by reference financial tables, interactive data files and other exhibits into the company’s shelf registration statements and equity compensation plans.
Investors can also review filings that describe capital markets activities, such as at-the-market (ATM) equity offering programs and changes to the ratio of American Depositary Shares (ADSs) to ordinary shares, which effectively function as reverse ADS splits. These documents outline the terms under which Chemomab may sell ADSs, the role of its sales agent, and related legal opinions. Additional 6-Ks report outcomes of shareholder meetings, including director elections, equity awards and auditor appointments.
For those analyzing Chemomab’s governance and regulatory status, the filings page is a central source for information on registration statements on Form F-3 and Form S-8, as well as references to risk factor discussions in the company’s Form 20-F. While detailed clinical protocols and scientific data are often summarized in attached press releases, the SEC filings frame how these developments fit into Chemomab’s overall business, financing strategy and regulatory obligations.
On Stock Titan, these documents are complemented by AI-powered tools that can summarize lengthy filings, highlight key sections related to nebokitug’s PSC program, and help users quickly locate information on topics such as liquidity, share structure changes, or the incorporation by reference of new disclosures into existing registration statements.
Chemomab Therapeutics Ltd. has adjourned its Annual General Meeting of Shareholders due to a lack of quorum. The meeting, originally scheduled for April 28, 2026 in Ramat Gan, Israel, has been postponed to May 5, 2026 at the same time and location.
The agenda and proposed resolutions remain as set out in the proxy statement furnished on March 20, 2026, which continues to govern the matters to be voted on. This report is also incorporated by reference into Chemomab’s existing Form F-3 and Form S-8 registration statements.
Chemomab Therapeutics Ltd. director and Chief Executive Officer Mor George Adi filed an initial ownership report showing his holdings in American Depositary Shares (ADSs), stock options, and RSUs. This Form 3 does not reflect new buying or selling activity; it establishes his existing equity position.
He holds options over 32,925 ADSs at an exercise price of $5.94 expiring in 2028 and options over 109,718 ADSs at $5.16 expiring in 2033, both directly. Indirectly, his spouse holds options over 8,431 ADSs at $3.20 expiring in 2026. Direct ADS holdings include 79,268, 31,712 and 18,750 shares, with an additional 50,059 ADSs held indirectly by his spouse. Footnotes describe RSU grants with quarterly vesting schedules through 2028 and 2029, highlighting that a portion of his equity exposure will vest over time rather than all at once.
Chemomab Therapeutics Ltd. director Darvish Nissim filed an initial ownership report showing existing equity interests in the company. The filing lists several stock options over American Depositary Shares with different exercise prices and expiration dates, alongside a smaller direct holding of 300 American Depositary Shares.
Multiple option grants, including those from October 28, 2016, April 19, 2021, March 7, 2022, March 21, 2023, and June 1, 2024, are fully vested and exercisable. Another grant from June 14, 2023 vests in 36 monthly installments and is scheduled to be fully exercisable by June 14, 2026.
Chemomab Therapeutics Ltd. director Neil Harris Cohen filed a Form 3 disclosing his initial beneficial ownership in the company’s American Depositary Shares. He directly holds 35,304 American Depositary Shares as of the reporting date.
He also holds several stock options to buy additional American Depositary Shares at exercise prices ranging from $2.14 to $109.04 per share, with expirations between 2030 and 2036. Footnotes state these options were granted between July 16, 2020 and March 16, 2025 and are all fully vested and exercisable as of the report date, showing his existing equity-based compensation position rather than new market transactions.
Chemomab Therapeutics Ltd. director Alan Charles Moses filed an initial Form 3 showing his holdings of stock options over American Depositary Shares. The filing lists several option grants at exercise prices ranging from $2.14 to $109.04 per ADS. According to the notes, these options are fully vested and exercisable as of the report date.
Chemomab Therapeutics Ltd. Chief Financial Officer Fatal Sigal filed an initial ownership report showing current holdings in American Depositary Shares (ADSs), stock options, and restricted share units. The filing lists three option grants over ADSs with exercise prices of $39.31, $8.44, and $6.80 per ADS, expiring between November 2031 and June 2033, along with multiple ADS and RSU positions that vest in stages through 2029.
Chemomab Therapeutics Ltd. Chief Development Officer John Lawler filed an initial Form 3 reporting his existing equity interests in the company. This filing does not show any new purchases or sales, only current holdings.
Lawler holds stock options over 12,500, 10,864 and 7,500 American Depositary Shares with exercise prices of $20.52, $5.68 and $2.20 per ADS, expiring in 2032, 2033 and 2034, respectively. Some of these options are already fully vested, while others vest in quarterly installments.
He also reports direct holdings of American Depositary Shares, including awards of RSUs granted in October 2024 and April 2025 that vest 25% on the first anniversary of grant and then in 12 quarterly installments of 6.25% until October 1, 2028 and April 10, 2029.
Chemomab Therapeutics Ltd. director Jill M. Quigley filed an initial statement of beneficial ownership that lists her stock option holdings over the company’s American Depositary Shares. The filing shows four option grants with different exercise prices and long-dated expirations.
Quigley holds options over 3,410 ADS at an exercise price of $13.00 per share expiring on June 16, 2032; 1,714 ADS at $6.80 expiring on June 14, 2033; 2,533 ADS at $4.00 expiring on June 16, 2034; and 3,959 ADS at $5.24 expiring on June 16, 2035. Footnotes state that options granted on June 16, 2022, June 14, 2023, and June 16, 2024 are fully vested and exercisable as of the report date.
Chemomab Therapeutics Ltd. director Claude Nicaise reported his initial holdings of stock options to buy the company’s American Depositary Shares. The filing lists six option awards with exercise prices ranging from $2.14 to $109.04 per share and expiration dates between 2031 and 2036. Footnotes state that options granted on April 19, 2021, March 7, 2022, March 21, 2023, March 18, 2024 and March 16, 2025 are fully vested and exercisable as of the report date. The Form 3 records ownership only and does not show any recent purchases or sales.
Chemomab Therapeutics, a clinical-stage Israeli biopharma company, filed its annual report outlining its business, key risks and financial position. The company focuses on nebokitug (CM-101), a monoclonal antibody targeting CCL24 for fibrotic and inflammatory diseases such as primary sclerosing cholangitis and systemic sclerosis.
As of December 31, 2025, Chemomab had 575,381,320 ordinary shares outstanding, equal to 7,192,276 ADSs. Cash, cash equivalents and deposits totaled $10.4 million, against an accumulated deficit of $111.6 million. Management expects existing cash to fund operations only through the end of the first quarter of 2027 and explicitly states substantial doubt about the company’s ability to continue as a going concern without raising additional capital.
The filing stresses that Chemomab has no approved products and is highly dependent on the success of nebokitug, which remains in clinical development and will require significant additional trials, regulatory approvals and funding. Extensive risk disclosures highlight clinical, regulatory, manufacturing, intellectual property, cybersecurity, geopolitical and Nasdaq listing risks, as well as potential dilution from future equity financings and volatility in the ADS trading price.